Navigation Links
MedQuist Reports Results for the Fourth Quarter and 2009
Date:3/12/2010

,391 (154) Other non-current assets 25 134 Accounts payable 1,038 (5,557) Accrued expenses (1,200) (12,701) Accrued compensation 1,192 (3,559) Deferred revenue (4,939) (272) Other non-current liabilities (307) (211) ---- ---- Net cash provided by (used in) operating activities $44,551 $(8,754) ------- ------- Investing activities: Purchase of property and equipment (4,932) (6,574) Proceeds from sale of investments - 692 Capitalized software (2,582) (3,411) Investment in affiliated company (852) - --- -- Net cash used in investing activities (8,366) (9,293) ------ ------ Financing activities: Dividends paid (49,949) (103,279) Debt issuance costs (1,201) - Proceeds from exercise of stock options - 68 -- -- Net cash used in financing activities (51,150) (103,211) ---
'/>"/>
SOURCE MedQuist Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. MedQuist Re-launches New, Improved Web Site
2. MedQuist Updates Status of Outstanding SEC Filings
3. MedQuist and MedAssets Sign Multi-Year Contract for Clinical Documentation Workflow Solutions
4. MedQuist Evaluating Whether a Sale of the Company is in the Best Interests of the Company and its Shareholders
5. MedQuist Files Preliminary Proxy Statement and Applies for Listing on NASDAQ
6. MedQuist Announces Appointment of Brian ODonoghue and Mark E. Schwarz to its Board of Directors
7. Leading Arizona Radiological Group Selects MedQuist for Speech Recognition Solution
8. MedQuist Announces Entry Into Settlement Term Sheet Resolving South Broward Litigation
9. MedQuist Technology Solutions to Power Documentation Workflow at New England Facility
10. MedQuist to Get New Majority Stakeholder
11. MedQuist Announces Dismissal of South Broward Litigation and Appointment of New Interim President & CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... La Mirada, CA (PRWEB) , ... June 29, ... ... organizations, has announced that Dr. Gabriel Martin Del Campo is their newest FAA-certified ... Administration (FAA) physical examination is available for all fledging pilots seeking to obtain ...
(Date:6/29/2015)... ... June 29, 2015 , ... The Society for Immunotherapy ... (EMA) has granted accelerated approval of Bristol-Myers Squibb’s Opdivo® (nivolumab) for the treatment ... the approval of nivolumab for patients with metastatic melanoma in Europe represents a ...
(Date:6/29/2015)... ... ... Displays and Exhibits , a top online retailer of trade ... that include branding. Enter price code brand2015 for a ten percent discount on all ... promotional materials, all should integrate the company logo to communicate the brand. What is ...
(Date:6/29/2015)... ... 29, 2015 , ... Brittenford Systems, a provider of financial ... businesses across the United States, has announced that it has been named to ... year. , Based on company revenue and number of employees, Bob Scott’s Top ...
(Date:6/29/2015)... ... June 29, 2015 , ... Human Factors and Usability ... 16, 2015 — 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/humanfactors , ... engineering to the design of new products as well as to postmarket surveillance ...
Breaking Medicine News(10 mins):Health News:Healthpointe Now Offering FAA Physical Exams in San Bernardino County 2Health News:Society for Immunotherapy of Cancer Reacts to EMA Approval of Nivolumab for Treatment of Metastatic Melanoma 2Health News:Society for Immunotherapy of Cancer Reacts to EMA Approval of Nivolumab for Treatment of Metastatic Melanoma 3Health News:Stock Up on Logo Branding Tools Reduced this Month and Next Month from Displays and Exhibits 2Health News:Brittenford Systems Celebrates Fifth Consecutive Year on Bob Scott Insights Top 100 VARs 2Health News:Brittenford Systems Celebrates Fifth Consecutive Year on Bob Scott Insights Top 100 VARs 3Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 2Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 3
... focused new and improved interface. The most highlighting feature of this ... consumers to choose and buy their niche medicines any time. ... ... most reliable online pharmacy, launched a brand new customer focused, well ...
... for Two to International DestinationsSALT LAKE CITY, April 5 ... destination -- by winning it, with the launch of their ... Advanced." Schiff(R) will award seven grand prize winners a ... eight international destinations as well as 10,000 secondary prizes of ...
... 4 Inverness Medical Innovations, Inc. (NYSE: ... take charge of their health at home through the ... that it will attend the upcoming Goldman Sachs Leveraged ... 8, 2009 at the Goldman Sachs Conference Center located ...
... maker of lubricious HYDAK® hydrophilic coatings, and Agion Technologies, the ... co-marketing agreement to develop and promote a coatings product line ... ... Horsham, PA (PRWEB) April 4, 2009 -- ...
... Inc. (Nasdaq: BNVI ), a leader in the ... areas of women,s health and cancer, is scheduled to present ... City on April 9, 2009 at 3:45 p.m. MST.Mary Tagliaferri, ... The purpose of the presentation will be to update investors ...
... Departments Urge Public to Self-Report Suspected MeaslesHARRISBURG, Pa., April 3 ... Allegheny County Health Department and UPMC,s Children,s Hospital of Pittsburgh ... seen at Children,s Hospital. Exposures to measles may have occurred ... , ...
Cached Medicine News:Health News:Rxonlinetoday Launch Cyber Shop for FDA Approved Medicines 2Health News:Rxonlinetoday Launch Cyber Shop for FDA Approved Medicines 3Health News:Schiff Announces New 'Trip of a Lifetime' Sweepstakes 2Health News:Schiff Announces New 'Trip of a Lifetime' Sweepstakes 3Health News:Biocoat and Agion to Develop and Co-market Coatings for Medical Devices. 2Health News:Biocoat and Agion to Develop and Co-market Coatings for Medical Devices. 3Health News:Bionovo to Present at the Cambria Capital Investor Meeting 2Health News:Bionovo to Present at the Cambria Capital Investor Meeting 3Health News:Pennsylvania State Department of Health and Allegheny County Health Department Confirm Four Cases of Measles in Southwest Region 2Health News:Pennsylvania State Department of Health and Allegheny County Health Department Confirm Four Cases of Measles in Southwest Region 3
(Date:6/29/2015)... SAN FRANCISCO , June 29, ... company,s novel blood-draw technology has received CE Mark ... quality from the European Union. This regulatory milestone ... alternative to one of the most common procedures ... Velano Vascular,s proprietary device reduces the ...
(Date:6/29/2015)... , June 29, 2015 ... and predicted revenues ,Where is the market for dermatological ... market? Visiongain ,s new report shows you potential ... and prospects. Our 310 page report ... most lucrative areas in the industry and the future ...
(Date:6/29/2015)... Calif. , June 29, 2015  The ... innovative features to cars on the basis of ... The industry is now on the verge of ... cars. While automotive HWW non-critical features such as ... be present in 30 to 40 percent of ...
Breaking Medicine Technology:Velano Vascular Receives CE Mark For Novel Blood Draw Technology Designed to Reduce Needle Exposures for Hospitalized Patients and Healthcare Providers 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 3Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 4Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 5Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 6Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 7Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 8Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 2Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 3Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 4
... Expected in November 2008, BOTHELL, Wash., Oct. 9 ... the completion of patient enrollment and dosing,for the third ... and,efficacy of its formulation of 12-hour extended-release (ER) ibuprofen ... top-line,results from this pivotal trial in November 2008. Ibuprofen ...
... Will Reduce Animal Use in Cosmetics and Chemicals ... Corp. today announced,that results of a recently completed ... EpiDerm in vitro human skin tissue,equivalent. The test ... to be accepted as a validated alternative to ...
Cached Medicine Technology:SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3MatTek's EpiDerm In Vitro Tissues Headed for Validation in Europe 2
... A concentrated enzymatic cleanser ... semi-automated hematology instruments. It ... all Abbott CELL-DYN® hematology ... instruments. The shelf life ...
Streck-CD3500 Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3500 and 3700. The shelf life is two years from the date of manufacture....
Streck-Diluent III Plus is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 3000, 3500 and 3700. The shelf...
Streck-Diluent IIIA is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 1700. The shelf life is one year f...
Medicine Products: